Abstract
Background: The aim of our study was to determine the frequency of anti-thyroid-stimulating hormone (TSH) receptor antibodies (TRAb) in Tunisian patients with Graves' disease (GD) and to compare the validity of TRAb to that of thyroperoxidase (TPO-Ab) and thyroglobulin antibodies (TG-Ab).
Methods: ELISA was used to determine the frequency of TRAb, TPO-Ab and TG-Ab in sera of 190 patients with GD. Patients were divided into four groups: those with untreated active GD (group A, n=71), those receiving treatment with anti-thyroid drugs (group B, n=85), those in relapse (group C, n=15) and those in remission (group D, n=19). Sera of 100 healthy blood donors served as controls.
Results: The sensitivity of TRAb for the diagnosis of GD (95.8%) was significantly higher than that of TPO-Ab (73.2%) and TG-Ab (42.2%) (p=0.0005 and p<10–7, respectively). The positive rate for TRAb was lower in group B than in group A (70.6% and 95.8%, respectively; p=0.0001). The levels of TRAb were significantly higher in group A than in group B (mean 30.1 and 14.2 IU/L, respectively; p=0.006).
Conclusions: TRAb, but neither TPO-Ab nor TG-Ab, is valuable in the diagnosis and management of patients with GD.
Clin Chem Lab Med 2007;45:26–9.
References
1. Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves' disease. Trends Endocrinol Metab2005;16:243–8.10.1016/j.tem.2005.05.009Search in Google Scholar
2. Ando T, Latif R, Davies TF. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract Res Clin Endocrinol Metab2005;19:33–52.10.1016/j.beem.2004.11.005Search in Google Scholar
3. Smith BR. Thyroid autoantibodies. Scand J Clin Lab Invest2001;61:45–52.10.1080/003655101753352040Search in Google Scholar
4. Orgiazzi J. Anti-TSH receptor antibodies in clinical practice. Endocrinol Metab Clin North Am2000;29:339–55.10.1016/S0889-8529(05)70135-3Search in Google Scholar
5. Orgiazzi J, Madec AM, Ducottet X. The role of stimulating, function-blocking and growth-blocking anti-TSH receptor antibodies (TRAbs) in GD, Hashimoto's disease and in atrophic thyroiditis. Ann Endocrinol2003;64:31–6.Search in Google Scholar
6. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab1999;84:90–7.10.1210/jcem.84.1.5415Search in Google Scholar
7. Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, et al. A new assay for thyrotropin receptor autoantibodies. Thyroid2004;14:830–5.10.1089/1050725042451248Search in Google Scholar
8. Kamijo K. TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor. Endocr J2003;50:113–6.10.1507/endocrj.50.113Search in Google Scholar
9. Kamijo K, Ishikawa K, Tanaka M. Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith. Endocr J2005;52:525–9.10.1507/endocrj.52.525Search in Google Scholar
10. Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol2001;54:89–96.10.1046/j.1365-2265.2001.01197.xSearch in Google Scholar
11. Shibayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, Matsuura N. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. Endocr J2005;52:505–10.10.1507/endocrj.52.505Search in Google Scholar
12. Alnaqdy A, Al-Maskari M. Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease. Med Princ Pract2005;14:209–12.10.1159/000085736Search in Google Scholar
13. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res2004;36:92–6.10.1055/s-2004-814217Search in Google Scholar
14. Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Horm Metab Res2005;37:745–50.10.1055/s-2005-921102Search in Google Scholar
15. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE; Basedow Study Group. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid2005;15:1047–54.10.1089/thy.2005.15.1047Search in Google Scholar
16. Hu YM, Liu W, Lu GH. Significance of combining tests of thyroid autoantibodies in differential diagnosis between Graves' disease and Hashimoto's hyperthyroidism. Zhonghua Yi Xue Za Zhi2003;83:940–2.Search in Google Scholar
17. Giovanella L, Ceriani L, Garancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO). Q J Nucl Med2001;45:115–9.Search in Google Scholar
18. Lian XL, Bai Y, Sun ML, Guo ZS, Dai WX. Clinical validity of anti-thyroperoxidase antibody and anti-thyroglobulin antibody. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2004;26:677–81.Search in Google Scholar
©2007 by Walter de Gruyter Berlin New York